Undisclosed Peptide Programs

About AmideBio

AmideBio is a private, preclinical-stage biotech focused on discovering peptide drug candidates for metabolic diseases. The company operates a dual business model, combining internal therapeutic discovery with a revenue-generating service arm offering custom synthesis and catalog peptides. Its core technology integrates computational design with a proprietary manufacturing process (BioPure™) to create and produce novel peptides efficiently. Leadership includes industry veterans with significant experience in drug development, particularly in diabetes.

About Lactocore

Lactocore Group is a private, preclinical-stage biotech firm based in Munich, Germany, founded in 2015. It is advancing a pipeline of peptide drugs targeting significant unmet needs in neurology and metabolism, utilizing a specialized discovery and optimization platform. The company operates as a pre-revenue entity, likely funded by venture capital and grants, positioning itself in the competitive but high-potential neuropeptide therapeutics space. Its success hinges on translating its platform technology into clinically validated candidates and securing strategic partnerships for development.

Therapeutic Areas

Other Metabolic Disease Drugs